Abstract
Mammaglobin is a gene that is expressed almost exclusively in the normal breast epithelium and human breast cancer. It is a member of the secretoglobin gene family and forms a heterodimer with lipophilin B. We have focused on the tissue-specificity of mammaglobin as a potential mechanism for the specific killing of breast cancer cells. By elucidating the promoter region of mammaglobin, we hope to utilize this site as a method for turning on the apoptosis inducer gene, Bax, in breast cancer cells. The Bax gene will only be expressed at levels necessary to induce apoptosis in mammaglobin positive cells. This would include > 80% of all breast cancer cells and some normal breast epithelium. This type of targeted killing could be conceptualized as a biochemical mastectomy; that is, genetic ablation of breast tumor cells and perhaps non-malignant breast epithelium while preserving the adipose and stromal components of the breast. Work is also being done to address the binding specificity of the secreted mammaglobin protein. There is early evidence that the mammaglobin heterodimer may in fact bind to breast and breast cancer cells. If this finding is validated, this creates the possibility that mammaglobin can be tagged with a radioisotope or a toxin, so that binding of the tagged-mammaglobin complex results in the specific killing of that breast cancer cell. Finally, mammaglobin is being explored as a target for immune-based interventions. In vitro studies have demonstrated that T cellmediated immune responses can be induced against mammaglobin-derived peptides expressed by MHC molecules on tumor cells and antigen-presenting cells. In summary, mammaglobin displays several unique features that make it a promising target for intervention.
Keywords: mammaglobin, breast cancer, diagnosis, therapy, apoptosis, antibody, t lymphocyte, vaccine
Current Cancer Drug Targets
Title: Mammaglobin-Based Strategies for Treatment of Breast Cancer
Volume: 4 Issue: 6
Author(s): Peter S. Goedegebuure, Mark A. Watson, Carsten T. Viehl and Timothy P. Fleming
Affiliation:
Keywords: mammaglobin, breast cancer, diagnosis, therapy, apoptosis, antibody, t lymphocyte, vaccine
Abstract: Mammaglobin is a gene that is expressed almost exclusively in the normal breast epithelium and human breast cancer. It is a member of the secretoglobin gene family and forms a heterodimer with lipophilin B. We have focused on the tissue-specificity of mammaglobin as a potential mechanism for the specific killing of breast cancer cells. By elucidating the promoter region of mammaglobin, we hope to utilize this site as a method for turning on the apoptosis inducer gene, Bax, in breast cancer cells. The Bax gene will only be expressed at levels necessary to induce apoptosis in mammaglobin positive cells. This would include > 80% of all breast cancer cells and some normal breast epithelium. This type of targeted killing could be conceptualized as a biochemical mastectomy; that is, genetic ablation of breast tumor cells and perhaps non-malignant breast epithelium while preserving the adipose and stromal components of the breast. Work is also being done to address the binding specificity of the secreted mammaglobin protein. There is early evidence that the mammaglobin heterodimer may in fact bind to breast and breast cancer cells. If this finding is validated, this creates the possibility that mammaglobin can be tagged with a radioisotope or a toxin, so that binding of the tagged-mammaglobin complex results in the specific killing of that breast cancer cell. Finally, mammaglobin is being explored as a target for immune-based interventions. In vitro studies have demonstrated that T cellmediated immune responses can be induced against mammaglobin-derived peptides expressed by MHC molecules on tumor cells and antigen-presenting cells. In summary, mammaglobin displays several unique features that make it a promising target for intervention.
Export Options
About this article
Cite this article as:
Goedegebuure S. Peter, Watson A. Mark, Viehl T. Carsten and Fleming P. Timothy, Mammaglobin-Based Strategies for Treatment of Breast Cancer, Current Cancer Drug Targets 2004; 4 (6) . https://dx.doi.org/10.2174/1568009043332862
DOI https://dx.doi.org/10.2174/1568009043332862 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Development of MSN-Gd<sup>3+</sup>-C595 as MR Imaging Contrast Agent for Prostate Cancer Cell Imaging
Current Molecular Imaging (Discontinued) Effects of Propolis and Caffeic Acid Phenethyl Ester (CAPE) on Breast Cancer Cells
Current Pharmacogenomics and Personalized Medicine Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Glioblastoma Multiforme Formation and EMT: Role of FoxM1 Transcription Factor
Current Pharmaceutical Design Binding of Tris to Bacillus licheniformis α-Amylase Can Affect Its Starch Hydrolysis Activity
Protein & Peptide Letters The ABC of the Blood-Brain Barrier - Regulation of Drug Efflux Pumps
Current Pharmaceutical Design Editorial [Hot topic: Natural Antioxidants and their Derivatives:Biology and Clinical Application (Guest Editors: Thea Magrone, Yoshio Kumazawa & Emilio Jirillo)]
Current Topics in Medicinal Chemistry Signal Transduction Therapy for Cancer - Whither Now?
Current Signal Transduction Therapy The Pharmacogenomics “Side-effect” of TP53/EGFR in Non-small Cell Lung Cancer Accompanied with Atorvastatin Therapy: A Functional Network Analysis
Anti-Cancer Agents in Medicinal Chemistry Propargyl 4-[18F]fluorobenzoate: A Putatively More Stable Prosthetic Group for the Fluorine-18 Labeling of Biomolecules via Click Chemistry
Current Radiopharmaceuticals (6-Bromo-1,4-dimethyl-9<i>H</i>-carbazol-3-yl-methylene)-hydrazine (Carbhydraz) Acts as a GPER Agonist in Breast Cancer Cells
Current Topics in Medicinal Chemistry Hyaluronan and Hyaluronan Synthases: Potential Therapeutic Targets in Cancer
Current Drug Targets - Cardiovascular & Hematological Disorders Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Heterogeneity Amongst 5-HT3 Receptor Subunits: Is this Significant?
Current Molecular Medicine Anticancer Effect of a Curcumin Derivative B63: ROS Production and Mitochondrial Dysfunction
Current Cancer Drug Targets Design and Synthesis of Some Newer Pyrimidine Hydroxamates as Histone Deacetylase Inhibitors
Current Enzyme Inhibition Multi-Targeted Histone Deacetylase Inhibitors in Cancer Therapy
Current Medicinal Chemistry False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of TNF and Its Family Members in Inflammation and Cancer: Lessons from Gene Deletion
Current Drug Targets - Inflammation & Allergy CYLD-Mediated Signaling and Diseases
Current Drug Targets